Patent attorney specialising in the life sciences, with experience in devising global patent strategies and challenging/defending patent rights at the Opposition Division and Board of Appeal of the European Patent Office. Main areas of expertise include inventions in the fields of antibodies, genetic engineering and biochemistry.
BSc (Hons), PhD, Fellow of the Chartered Institute of Patent Attorneys, European Patent Attorney, Patent Attorney Litigator.
Research/Industry experience: Sept 1995 - Sept 1996: Industrial research at Novartis; Jan 1998 - Sept 1998: Industrial research at AstraZeneca; Jan 2001 - Jun 2003: Postdoctoral Research Fellow at Imperial Cancer Research Fund (now Cancer Research UK).
Mark studied microbiology and virology at the University of Warwick and obtained a PhD in Molecular Cell Biology at the same university. His studies included research placements at AstraZeneca in the UK, and Novartis in Austria.
Mark subsequently completed a two-year post-doctoral fellowship in mammalian molecular biology at Imperial Cancer Research Fund (now Cancer Research UK) in Dundee. His research has been published in peer-reviewed journals including Journal of Biological Chemistry and Nature.
Mark joined Potter Clarkson in 2003 and became a partner in 2011. He specialises in the field of biotechnology, including screening assays, gene therapy approaches and recombinant DNA technologies. In 2005, Mark was awarded the Moss Prize for obtaining the highest overall mark in the foundation level patent examination papers. Mark is listed as an IP Star by Managing Intellectual Property for 2017.
In 2014, Mark qualified as a Patent Attorney Litigator and was awarded a Higher Courts Litigation Certificate, allowing him to conduct litigation in the High Court and the Court of Appeal, in addition to having a right of audience in the Intellectual Property Enterprise Court.
Examples of clients:
- BioInvent International AB
- Capnova A/S portfolio companies
- Lonza Group
- Medical Research Council Technology
- Novozymes A/S
- ValiRx plc